A malignant fibrous histiocytoma of the breast

We have experienced treating a 49-year-old female with a malignant fibrous histiocytoma (MFH) arising from the right mammary gland. Nine months after surgery, lung metastasis occurred but the lung lesion proved to be resectable. Our findings suggested that the primary lesion had originated from a phyllodes tumor. MFH arising from the mammary gland is an extremely rare tumor, and only 12 such cases have been reported including that of our patient.     

Long survival in a case of metastatic brain tumor

A 45-year-old man was admitted after resection of a metastatic brain tumor (papillary adenomatous adenocarcinoma, well differentiated) for both therapy and a search for the primary and any other metastatic lesions. An extensive general examination revealed no evidence of malignant lesion except for fibrous change in the right lung apex by roentgenography and CT scan. Histological examination of the right upper lobe and group II lymph nodes revealed a scar cancer presenting the same histology but no evidence of metastasis. The patient, who received CAP and FVM alternately, is currently healthy with no recurrence after 4 years.     

The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma

We report a case of fifties man. He admitted to our hospital due to a hypochondralgia. Computed tomography revealed a tumor of right adrenal gland and a tumor of upper lobe of the right lung. Adrenal tumor had rapidly increased, so we performed adrenectomy. At first adrenal tumor was diagnosed as primary adrenal cancer because its histological findings did not coincide with those of common histologic types of lung cancer. As there were possibilities that one of adrenal or lung tumor was primary and the other was metastatic or both of the two were double primary, we performed right upper lobectomy. Lung tumor was diagnosed as primary pleomorphic carcinoma containing spindle-shaped tumor cells and adenocarcinoma, and then the diagnosis of adrenal tumor was corrected as metastasis of lung cancer. Two months after the lung operation, cervical lymph node swelling, metastasis of stomach and local recurrence of adrenal tumor appeared. After he underwent six courses of systemic chemotherapy of carboplatin and paclitaxel, a clinical complete response was obtained and no recurrence is observed for 4 years.     

Fibrolipomatous Hamartoma of the Lung: A Case Report and Review of the Literature

A fibrolipomatous hamartoma of the lung in a 57-year-old Japaneseman is reported. Computed tomography revealed an abnormal masswith fatty and soft tissue densities in the upper portion ofthe right lung, indicating a liposarcoma. Upon resection, thetumor was found to consist of a 7.5 x 4.0 cm soft, yellowishmass continuous with a 3.0 x 1.5 cm polyp. The tumor was composedprimarily of mature fibro-adipose tissue with some glandularand cartilaginous components, which identified it as a fibrolipomatoushamartoma. Follow-up studies of the patient for two years aftersurgery found no sign of malignancy. Thus, lipomatous or fibrolipomatoushamartoma should be considered as a possible diagnosis wheneveratypical lipomatous lung tumors are encountered.     

A case report of intrahepatic cholangiocarcinoma diagnosed as lung cancer with liver metastasis treated with radiofrequency ablation

In December 2008, a 43-year-old male who had been pointed out a nodular shadow in the right upper field on a chest radiography was admitted to hospital. A 35 mm mass infiltrating to superior vena cava in the right upper lobe of the lung, and 32 mm mass in the liver at S7 were detected by CT. Pathological diagnosis of the liver tumor was adenocarcinoma. Under the diagnosis of lung carcinoma and liver metastasis, systemic chemotherapy was started from January 2009. Radiofrequency ablation (RFA) therapy was added for liver S7 mass in February, and radiation therapy was performed for lung mass in December. The lung lesion has markedly reduced, but the liver lesion recurred in October 2009, which continued to grow up to 80 mm until August 2010. He presented to our hospital with the diagnosis of liver metastasis of controlled primary lung cancer. In October, we performed right hepatectomy with diaphragma and right lung resection. The pathological diagnosis was intrahepatic cholangiocarcinoma. Multiple recurrences in remnant liver, lung and peritoneal metastasis were detected in January 2011. For intrahepatic cholangiocarcinoma, hepatectomy is the only established treatment, and RFA treatment remains controversial. Clinical diagnosis of multiple cancers should be decided with caution.     

Primary malignant fibrous histiocytoma of the lung. A clinicopathologic and ultrastructural study of five cases

Primary sarcomas of the lung are rare malignant neoplasms which have usually been classified as fibrosarcomas or as leiomyosarcomas. Only five cases of primary malignant fibrous histiocytoma (MFH) of the lung have previously been reported in the literature. The authors reviewed 10 cases of primary pulmonary sarcoma of the lung seen at their institution during the last 12 years, and five of these cases met the morphologic criteria for the diagnosis of MFH. The morphology in these cases is identical to MFH of other body locations, and shows a combination of fibroblast-like and histiocyte-like cells at both the light and electron microscopic level. By electron microscopic examination there was no evidence for anaplastic carcinoma, rhabdomyosarcoma, or leiomyosarcoma. Of the three patients with adequate follow-up, one patient is alive without evidence of disease at 10 years, one died at 5 years without evidence of recurrent sarcoma, and one died at 7 months with liver metastasis. Two other patients are alive without recurrence at 8 months and 1 year, respectively, following surgery. Because MFH is primarily a tumor of the soft tissues of the extremities, patients with MFH of the lung must be carefully evaluated to rule out a metastatic origin. The reported prognosis in patients with primary MFH of the lung is poor, but early surgical resection does offer the possibility of a cure.     

Primary malignant fibrous histiocytoma of spleen with spontaneous rupture: a case report and literature review

Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma that mainly occurs in the lower and upper extremities, trunk and retroperitoneum. However, primary MFH of the spleen is especially rare. Only 11 cases of splenic MFH have been reported in the English literature. In this report, we describe a 35-year-old man who was found to have a large accumulation of free fluid in the abdominal cavity and a tumor mass 6 cm in diameter with rupture within the spleen by the abdominal ultrasonography. A splenectomy was performed and the histological diagnosis was malignant fibrous histiocytoma. The patient died 7 months after the operation as a result of generalized metastasis. Compared with the 11 previously documented patients of splenic MFH, our patient is the youngest and the first case with spontaneous rupture, which makes our case exceedingly rare. A literature review of primary MFH of spleen is also provided.     

原发性中叶肺癌的特征及外科治疗

目的 回顾分析原发性中叶肺癌的临床特征及外科治疗结果。方法从1976年至1998年，治疗原发性中叶肺癌123例，均采取手术治疗。结果手术方式：单纯中叶切除32例，中叶袖状切除5例，中上叶切除或中下叶切除术86例。结论中叶原发性肺癌发病率低(10．4％)，多见于女性。病变常累及上叶或下叶，中叶支气管旁淋巴结转移常见。单纯中叶切除难度大，常需行中上叶或中下叶切除，中叶袖状切除由于并发症多宜慎用。     

An Unusual Case of Bronchial Carcinoid Predominantly Consisting of Large Cells

A 58-year-old woman presented an unusual variant of bronchialcarcinoid. A tumor measuring 20 x 25 mm was recognized upongross examination in the upper lobe of the right lung. Microscopically,the tumor consisted of large polyhedral cells with a pseudoglandulararrangement similar to pheochromocytoma cells. Immunohistochemically,the tumor cells contained serotonin, S-100 protein and neuron-specificenolase. Thus, we consider this neoplasm to be a large cellvariant of bronchial carcinoid which, to our knowledge, hasnot been described in the literature     

Effective treatment of AFP-producing lung cancer with UFT

The main form of chemotherapy for non small cell lung cancer is a multiple combination therapy centered on cisplatin (CDDP). We herein report a case in which a favorable course was obtained for a patient with extremely rare AFP-producing lung cancer by single oral administrations of UFT, following extirpation of brain metastasis. The patient was an 80-year-old male whose main complaints were headache and aphasia. Following close examination, a diagnosis was made of moderately differentiated adenocarcinoma with the primary lesion in S6 of the right lung. A metastatic lesion was found in the left occipital lobe. Blood AFP was an abnormally high 17,000 ng/ml. No tumorous lesions were found in the liver. The brain metastasis were extirpated to alleviate cranial nerve symptoms, and the tissue was found to be the same as that of the primary lesion. AFP staining of the tumor tissue revealed positive cells. Because there was proliferation in the primary tumor following surgery, administration of UFT (300 mg/day Tegafur) was begun. Four weeks later the tumor had begun to shrink, and at 15 weeks was judged to be a partial response. A reduction in AFP was also seen. The patient showed absolutely no side effects from UFT, thus enabling outpatient treatment. Good results were obtained both in reducing the tumor and in maintaining the patient's quality of life.     

A case of pulmonary adenocarcinoma accompanied by superior vena caval thrombosis in a patient with peutz-jeghers syndrome

A case of lung adenocarcinoma and extensive deep vein thrombosis in a patient with Peutz-Jeghers syndrome (PJS) is presented. A 31-year-old Chinese man complained of shoulder pain and swelling of the right arm. A series of diagnostic procedures revealed a primary adenocarcinoma in the left upper lobe with cervical and supraclavicular lymph node metastases accompanied by deep vein thrombosis in the superior vena cava and right jugular vein. In addition, typical pigmentation of the lips and oral mucosa and multiple hamartomas in the stomach, duodenum and colon led to the diagnosis of PJS. PJS is known to be associated with increased risk of malignancies, especially in the gastrointestinal tract, breast, genitals and pancreas. As bronchoscopic examination showed no hamartomatous lesions in the bronchi, the development of primary lung cancer in this young patient might be independent of any hamartomatous lesion and might be associated with some genetic factors relating to PJS.     

A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy

We performed multimodal therapy for a huge hepatocellular carcinoma with tumor embolism (Vv3), for which excision was judged impossible. After treatment, a hepatectomy to the primary lesion was finally carried out and long-term survival was achieved. A 52-years-old man with right lateroabdominal pain had a huge occupied hepatocellular carcinoma that was detected in October 2000. A tumor embolism, which invaded the inferior vena cava, was also seen. The residual liver was judged to have insufficient capacity for a right hepatic lobectomy. A percutaneous transhepatic portal embolism (PTPE) was carried out against the right portal vein to increase in the left lobe capacity. The chemo-radiotherapy (36 Gy to the right hepatic vein and systemic administration of CDDP) and transcatheter arterial chemoembolization were added to the feeding arteries of the hepatic tumor. When a decrease in the postcaval vein tumor embolism was observed, the extended right hepatic lobectomy was performed. The postoperative course was good, and the patient was discharged from the hospital on postoperative day 41. Though lung metastasis and new lesions in left lobe were seen in a recurrence, two years and ten months since the start of the systemic chemotherapy. This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.     

肺腺鳞癌淋巴结转移规律的探讨

目的 分析肺腺鳞癌淋巴结转移(LNM)的特点.方法 对361例肺腺鳞癌患者的临床资料进行回顾性分析.淋巴结分区和TNM分期采用国际抗癌联盟(UICC)标准(1997年).统计分析采用χ2检验、Log rank检验和Cox比例风险模型分析.结果 361例肺腺鳞癌纵隔LNM途径表现为:左肺上叶癌首先转移到主.肺动脉窗淋巴结,右肺上叶癌首先转移到下气管旁淋巴结,两侧下叶肺癌首先转移到隆突下淋巴结,右肺中叶肺癌以向上转移为主.纵隔淋巴结跳跃转移以隆突下最为多见,其次为主-肺动脉窗和下段气管旁.发生单一站纵隔淋巴结跳跃转移的患者预后好于其他LNM者.结论 不同部位肺腺鳞癌的LNM途径和跳跃转移部位有所不同,治疗时应加以考虑.不同转移模式的患者预后不同,发生单一站纵隔淋巴结跳跃转移的患者预后可能较好.